A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

• Status: Active, not recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Incyte Corporation

Criteria

Inclusion Criteria:

• Have completed the final active treatment visit for an originating study eligible to enroll participants directly into study BREEZE-AD3 OR

• Meet criteria for NCT03334396 or NCT03334422.

Exclusion Criteria:

• Had investigational product permanently discontinued at any time during a previous baricitinib study.

• Had temporary investigational product interruption continue at the final study visit of a previous baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study.